SpringWorks Therapeutics Q2 2024 GAAP EPS $(0.54) Beats $(1.13) Estimate, Sales $59.733M Beat $34.343M Estimate
Author: Benzinga Newsdesk | August 07, 2024 06:38am
SpringWorks Therapeutics (NASDAQ:
SWTX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(1.13) by 52.21 percent. This is a 56.8 percent increase over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $59.733 million which beat the analyst consensus estimate of $34.343 million by 73.93 percent.
Posted In: SWTX